v3.26.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Operating expenses:    
Research and development $ 454,000 $ 112,337
General and administrative 648,229 1,167,502
General and administrative affiliates 740,280 943,229
Total operating expenses 1,842,509 2,223,068
Loss from operations (1,842,509) (2,223,068)
Other expenses:    
Loss of issuance 488,253
Change in FV of Derivative (216,701) 133,121
Interest expense (134,314) (84,240)
Interest expense affiliate (51,876) (8,340)
Amortization of Intellectual Property (11,544) (7,950)
Debt forgiveness 133,867
Debt discount amortization (677,781)
Total other expenses (280,568) (156,937)
Net loss before provision for income taxes (2,123,077) (2,380,005)
Provision for income taxes
Net loss (2,123,077) (2,380,005)
Net loss attributable to the non-controlling interest 13,324
NET LOSS ATTRIBUTABLE TO BIOXYTRAN $ (2,123,077) $ (2,366,681)
Loss per common share, basic $ (0.02) $ (0.02)
Loss per common share, diluted $ (0.02) $ (0.02)
Weighted average number of common shares outstanding, basic 91,843,409 138,598,691
Weighted average number of common shares outstanding, diluted 91,843,409 138,598,691